Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jost

Showing results (151-160 of 202) with videos related to

Pageof 21
Sort By:
Oncotarget|May 1, 2018
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profileVeronika Reidel, Johanna Kauschinger, Richard T Hauch, et al.
JACC. Cardiooncology|January 13, 2025
Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint InhibitorsFlorian Moik, Jakob M Riedl, Dominik Barth, et al.
Cancer Medicine|March 17, 2022
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer studyDominik A Barth, Stefanie Stanzer, Jasmin Spiegelberg, et al.
Journal of Cancer Research and Clinical Oncology|October 16, 2021
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategiesTimo O Odinius, Lars Buschhorn, Celina Wagner, et al.
ESMO Open|April 1, 2026
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from AustriaN Dobrić, S O Hasenleithner, C Suppan, et al.
Experimental Hematology & Oncology|April 25, 2019
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseStefanie Jilg, Richard T Hauch, Johanna Kauschinger, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Frontiers in Immunology|April 18, 2022
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer StudyDominik A Barth, Stefanie Stanzer, Jasmin A Spiegelberg, et al.
Thrombosis and Haemostasis|July 13, 2021
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-PaclitaxelJakob M Riedl, Esther Schwarzenbacher, Florian Moik, et al.
JCI Insight|March 25, 2021
PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancerLucia Liotta, Sebastian Lange, H Carlo Maurer, et al.
Pageof 21

Showing results (151-160 of 202) with videos related to

Sort By:
Pageof 21
Oncotarget|May 1, 2018
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profileVeronika Reidel, Johanna Kauschinger, Richard T Hauch, et al.
JACC. Cardiooncology|January 13, 2025
Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint InhibitorsFlorian Moik, Jakob M Riedl, Dominik Barth, et al.
Cancer Medicine|March 17, 2022
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer studyDominik A Barth, Stefanie Stanzer, Jasmin Spiegelberg, et al.
Journal of Cancer Research and Clinical Oncology|October 16, 2021
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategiesTimo O Odinius, Lars Buschhorn, Celina Wagner, et al.
ESMO Open|April 1, 2026
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from AustriaN Dobrić, S O Hasenleithner, C Suppan, et al.
Experimental Hematology & Oncology|April 25, 2019
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseStefanie Jilg, Richard T Hauch, Johanna Kauschinger, et al.
JAMA Oncology|May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-upHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Frontiers in Immunology|April 18, 2022
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer StudyDominik A Barth, Stefanie Stanzer, Jasmin A Spiegelberg, et al.
Thrombosis and Haemostasis|July 13, 2021
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-PaclitaxelJakob M Riedl, Esther Schwarzenbacher, Florian Moik, et al.
JCI Insight|March 25, 2021
PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancerLucia Liotta, Sebastian Lange, H Carlo Maurer, et al.
Pageof 21